Quick Read
-
Regeneron surged 13.55% after Q3 EPS of $20.07 crushed the $16.19 estimate, with revenue up 36% year over year.
-
IBB rose 1.25% and XLV gained 1.8% as Regeneron's rally flowed into cap-weighted health care and biotech ETFs.
-
Stacking an S&P 500, Nasdaq-100, health care ETF, and biotech fund can silently concentrate retirement accounts in the same large biotechs.
-
Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Regeneron didn't make the cut. Enter your email to see the names that beat REGN. The report is free. Enter your email and see if any of your stocks made the cut.
Regeneron( NASDAQ:REGN ) shares rose 13.55% in Friday's session, trading at $929.69 as of 9:45 AM ET on Oct 30, 2026. For a biotech worth roughly $94.03 billion, a double-digit move matters for more than its own shareholders. It flows straight into the health care and biotech index funds that sit in millions of retirement accounts.
Earnings Beat Lit the Fuse Before the Open
The catalyst was Regeneron's third-quarter earnings report, released before the market opened. Non-GAAP EPS came in at $20.07, well ahead of the $16.1941 consensus estimate. Revenue reached $5.1158 billion, up 36.27% year over year and beating the $4.56194128 billion estimate.
Sanofi collaboration revenue climbed 68% to $2.724 billion on Dupixent strength and the full repayment of the Sanofi development balance. U.S. EYLEA HD sales rose 62% and Libtayo grew 51%. Management also raised full-year non-GAAP gross margin guidance to approximately 86% from 84%–85%. The chief executive called it "an exceptional quarter by every measure."
Which Health Care ETFs Own Regeneron Right Now
Regeneron is a component of the S&P 500 and the Nasdaq-100, so it appears in broad index funds, though at a weight small enough that today's move barely shows. The sector funds tell a more useful story.
Free Report, Just Released
Why Didn't REGN Make The Top 10 List?
24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now . Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.
And REGN didn't make the cut!
The report is free, and you can see why we think each stock is a top investment today.
Enter Your Email and See the Ten →
| ETF |
REGN Weight |
Today's Move |
Expense Ratio |
|---|---|---|---|
| XLV |
1.08% |
+1.8% |
Not disclosed |
| XBI |
0.96% |
Not available |
Not disclosed |
| IBB |
Not disclosed |
+1.25% |
0.44% |
| VHT |
Not disclosed |
Not available |
0.09% |
The Health Care Select Sector SPDR Fund( NYSEARCA:XLV ) held 705,889 Regeneron shares worth $440,150,027.06 as of June 30, 2026. At about 1.08% of assets, Regeneron's surge adds roughly 0.15 percentage points to the fund. XLV's 1.8% gain this morning therefore reflects a broader health care bid, with Regeneron providing only part of the lift.
The SPDR S&P Biotech ETF( NYSEARCA:XBI ) uses an equal-weighted approach, so Regeneron sits beside small-cap names like Apogee Therapeutics at 1.49% and Moderna at 1.41%. Its June weight means a contribution of roughly 0.13 percentage points from today's move.
The cap-weighted iShares Biotechnology ETF( NASDAQ:IBB ) rose 1.25% early in the session. Because IBB weights by market value, a mega-cap like Regeneron typically ranks near the top of the fund, making it the most direct ETF channel for this rally. The Vanguard Health Care ETF( NYSEARCA:VHT ) offers similar broad sector exposure to XLV at a 0.09% expense ratio.
Regeneron Trailed Its Sector Funds Until Today
Even after this jump, Regeneron is up 20.91% year to date, behind XLV's 22.52% and IBB's 30.83%. The one-month picture looks different: Regeneron gained 23.87%, against 9.73% for XLV and 4.53% for IBB. Fund holders got this catch-up rally automatically, without picking the stock.
Overlap Risk Retirement Savers Often Miss
Concentration in XLV comes mainly from Eli Lilly, at 16.51% of net assets, and Johnson & Johnson, at 10.64%. Regeneron is a mid-tier position. Overlap builds up when an investor piles funds: an S&P 500 index fund, a Nasdaq-100 fund, a health care ETF and a cap-weighted biotech fund can all own the same large biotechs. Each layer adds exposure to the same handful of names.
Investors who want broader biotech participation with less single-name dependence can compare XBI's equal-weight design with IBB's cap weighting. The two funds will respond very differently the next time a mega-cap biotech jumps or falls on a single earnings report.
Upcoming Catalysts That Could Move These Funds Again
Regeneron expects an FDA decision on cemdisiran in generalized myasthenia gravis next month. It also hosts an investor roundtable on November 10, 2026, and a $1.0 billion Sanofi up-front payment will be recorded as revenue in the fourth quarter. On the risk side, U.S. sales of the original EYLEA fell 41% under biosimilar pressure. ETF holders should keep an eye on the stock, along with each fund's next holdings update, to see what portion of this rally reaches their portfolios.
Got $1,000? Before You Buy REGN, Read This
If you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And REGN wasn't one of them.
They combed the entire market. It's not 10 ideas, not 10 stocks everyone is talking about, it's what their research points to as the 10 best stocks to buy right now, and it's free. Read more here and see which stocks made the list -->>
Contact editorial@247wallst.com for any questions or corrections.
